JP2015509950A5 - - Google Patents

Download PDF

Info

Publication number
JP2015509950A5
JP2015509950A5 JP2014559248A JP2014559248A JP2015509950A5 JP 2015509950 A5 JP2015509950 A5 JP 2015509950A5 JP 2014559248 A JP2014559248 A JP 2014559248A JP 2014559248 A JP2014559248 A JP 2014559248A JP 2015509950 A5 JP2015509950 A5 JP 2015509950A5
Authority
JP
Japan
Prior art keywords
oligopeptide
acylated peptide
terminal acylated
peptide
terminal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014559248A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015509950A (ja
JP6382111B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2013/054177 external-priority patent/WO2013128003A1/en
Publication of JP2015509950A publication Critical patent/JP2015509950A/ja
Publication of JP2015509950A5 publication Critical patent/JP2015509950A5/ja
Application granted granted Critical
Publication of JP6382111B2 publication Critical patent/JP6382111B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014559248A 2012-03-01 2013-03-01 N末端改変オリゴペプチド及びその使用 Expired - Fee Related JP6382111B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP12157616.9 2012-03-01
EP12157616 2012-03-01
US201261625896P 2012-04-18 2012-04-18
US61/625,896 2012-04-18
PCT/EP2013/054177 WO2013128003A1 (en) 2012-03-01 2013-03-01 N-terminally modified oligopeptides and uses thereof

Publications (3)

Publication Number Publication Date
JP2015509950A JP2015509950A (ja) 2015-04-02
JP2015509950A5 true JP2015509950A5 (https=) 2016-04-21
JP6382111B2 JP6382111B2 (ja) 2018-08-29

Family

ID=49081680

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014559248A Expired - Fee Related JP6382111B2 (ja) 2012-03-01 2013-03-01 N末端改変オリゴペプチド及びその使用

Country Status (5)

Country Link
US (1) US20150038435A1 (https=)
EP (1) EP2820150A1 (https=)
JP (1) JP6382111B2 (https=)
CN (1) CN104136626B (https=)
WO (1) WO2013128003A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY36870A (es) * 2015-08-28 2017-03-31 Hanmi Pharm Ind Co Ltd Análogos de insulina novedosos
EP4067368A1 (en) 2016-06-01 2022-10-05 Athira Pharma, Inc. Compounds
RU2764197C1 (ru) 2016-09-23 2022-01-14 Ханми Фарм. Ко., Лтд. Аналоги инсулина с пониженной аффинностью к рецептору инсулина и их применение
US20190352358A1 (en) * 2017-02-06 2019-11-21 Alize Pharma Iii Sas Compounds, compositions and uses thereof for improvement of bone disorders
AR111341A1 (es) 2017-03-23 2019-07-03 Hanmi Pharm Ind Co Ltd Un conjugado del análogo de insulina con afinidad reducida para el receptor de insulina y uso del mismo
EP3728304B1 (en) 2017-12-21 2025-02-12 Bachem Holding AG Solid phase synthesis of acylated peptides
US20210045419A1 (en) * 2018-02-20 2021-02-18 University Of Manitoba Food Protein-Derived Peptides as Bitter Taste Blockers
CN112566653A (zh) * 2018-05-24 2021-03-26 阿莫利特制药公司 Igfbp-2的肝素结合域在治疗代谢紊乱中的作用
CN112367968B (zh) * 2018-07-06 2023-06-16 安医健有限公司 包含肽复合物作为有效成分的用于去除或吸附微尘的化妆品组合物
KR102507392B1 (ko) * 2020-06-18 2023-03-08 애니젠 주식회사 유기산-올리고펩타이드 복합체를 유효성분으로 포함하는 피부 노화 및 주름 개선용 조성물
EP4211468A4 (en) 2020-09-11 2024-10-09 Glympse Bio, Inc. DETECTION OF EX VIVO PROTEASE ACTIVITY FOR DETECTION/DIAGNOSTIC, STAGING, MONITORING AND TREATMENT OF DISEASES
WO2022159395A1 (en) 2021-01-20 2022-07-28 Viking Therapeutics, Inc. Compositions and methods for the treatment of metabolic and liver disorders
MX2024003236A (es) 2021-09-15 2024-06-19 Viking Therapeutics Inc Composiciones y metodos para el tratamiento de trastornos metabolicos y hepaticos.
WO2023172648A2 (en) * 2022-03-09 2023-09-14 Glympse Bio, Inc. Fluorogenic substrates for aminopeptidase detection in biofluids
US20230322689A1 (en) * 2022-04-08 2023-10-12 SunVax mRNA Therapeutics Inc. Ionizable lipid compounds and lipid nanoparticle compositions

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05213990A (ja) * 1991-02-27 1993-08-24 Taisho Pharmaceut Co Ltd トリペプチド誘導体
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
GB9409496D0 (en) * 1994-05-12 1994-06-29 London Health Ass Method for improving glycaemic control in diabetes
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
CA2343934A1 (en) * 1998-09-25 2000-04-06 The Children's Medical Center Corporation Short peptides which selectively modulate the activity of protein kinases
FR2864085B1 (fr) * 2003-12-18 2010-09-17 Centre Nat Rech Scient Nouveaux modulateurs du proteasome
JP2008513533A (ja) * 2004-09-23 2008-05-01 ゲルベ Cestイメージング用の造影剤封入システム
CN101155825B (zh) * 2005-02-09 2014-11-26 赫里克斯生物医疗公司 抗微生物六肽
DE102006047529A1 (de) * 2006-10-07 2008-04-10 Evonik Goldschmidt Gmbh Oligopeptide enthaltende dermatologische Zusammensetzungen zur Steigerung der Hautempfindlichkeit und der neuronalen Reizwahrnehmung
KR20090115852A (ko) * 2007-01-19 2009-11-09 카이 파마슈티컬즈 안정성 및 전달 효율을 증가시키기 위한 펩타이드 조성물의 변형
WO2008128038A2 (en) * 2007-04-13 2008-10-23 The Scripps Research Institute Methods and compositions for treating cardiac dysfunctions
US20110144010A1 (en) 2007-06-01 2011-06-16 Novo Nordisk A/S Spontaneously Dispersible Preconcentrates Including a Peptide Drug in a Solid or Semisolid Carrier
EP2190872B1 (en) 2007-09-05 2018-03-14 Novo Nordisk A/S Glucagon-like peptide-1 derivatives and their pharmaceutical use
ES2342754B1 (es) * 2008-10-03 2011-05-11 Lipotec, S.A. Peptidos utiles en el tratamiento y/o cuidado de la piel, mucosas, cuero cabelludo y/o cabello y su uso en composiciones cosmeticas o farmaceuticas.
WO2010060667A1 (en) 2008-11-28 2010-06-03 Novo Nordisk A/S Pharmaceutical compositions suitable for oral administration of derivatized insulin peptides
CA2786953A1 (en) * 2010-01-12 2011-07-21 Florian Anders Foeger Pharmaceutical compositions for oral administration of insulin peptides
US8809012B2 (en) * 2010-08-23 2014-08-19 Postach Academy-Industry Foundation Labeling agent and methods for simultaneous sequencing and quantification of multiple peptides and proteins using the same
CN102219850A (zh) * 2011-05-03 2011-10-19 上海格尼生物技术有限公司 新的长效glp-1化合物
CN102311483A (zh) * 2011-07-13 2012-01-11 大连伊美生物科技有限公司 一种低溶血性抗菌脂肽及其制备方法

Similar Documents

Publication Publication Date Title
JP2015509950A5 (https=)
Kimura et al. KMI-358 and KMI-370, highly potent and small-sized BACE1 inhibitors containing phenylnorstatine
JP2019533722A5 (https=)
ES2449615T3 (es) Péptidos y su uso
JP5378998B2 (ja) 炎症性メディエーターの放出を減弱させるための方法及びそれにおいて有用なペプチド
NO20071369L (no) Antimikrobiske peptider omfattende et arginin- og/eller lysin-inneholdende motiv
CN103476792B (zh) 人乳铁蛋白衍生肽及其用途
JP2012506442A5 (https=)
HRP20171048T1 (hr) Novi agonisti angiotenzinskog receptora tipa 2 (at2) i njihove upotrebe
JP2010512326A5 (https=)
WO2007061829A3 (en) Pharmaceutical composition
WO2008047370A3 (en) Compositions and methods for inducing angiogenesis
ES2387435B1 (es) Uso de heptapéptidos para el control de la hipertensión
WO2008096816A1 (ja) 血管新生誘導剤及びそれに用いられるポリペプチド
JP2019534247A5 (https=)
AU2003264679A8 (en) Peptides having antimicrobial properties and compositions containing same in particular for preserving foods
Rall et al. Boswellic acids and protease activities
JP2021531246A5 (https=)
BR112012012190A2 (pt) peptídeo, método e kit de diagnóstico e composição farmacêutica
JP2015533821A5 (https=)
JP2013529600A5 (https=)
Bose et al. Camostat in COVID-19
ES2321358B1 (es) Uso de peptidos derivados de la lactoferrina para preparar formulaciones inhibidoras de la enzima conversora de angiotensina i.
JP2008007448A5 (https=)
JP2005523284A5 (https=)